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ABSTRACT
Background: The purpose of our study was to assess the use of opioids before and after 
hip fracture in elderly patients in order to determine the effect of opioid use on all-cause 
mortality, and to analyze how the history of opioid use before fracture increases the risk of 
sustained use following hip fracture using a Korea nationwide cohort.
Methods: Our study identified hip fracture patients from the Korean National Health 
Insurance Service-Senior cohort. The index date was defined as 90-days after admission to 
the acute care hospital that fulfilled the eligibility criteria of elderly hip fracture. Patients 
were classified into past user, current user, and sustained user according to the use of opioid 
at each period based on the time of admission and index date. The opioids were classified 
into strong opioids and tramadol. A generalized estimating equation model with a Poisson 
distribution and logarithmic link function was performed to estimate the adjusted rate 
ratios (aRRs) and 95% confidence intervals (CIs) to assess the association between past use 
and sustained use. A multivariable-adjusted Cox proportional hazard model was used to 
investigate the effects of strong opioid and tramadol use on all-cause mortality.
Results: A total of 12,927 patients were included in our study. There were 7,384 (57.12%) 
opioid past-users, 11,467 (88.71%) opioid current-users, and 7,172 (55.48%) sustained users. 
In comparison of the death risk according to current use or the defined daily dose of the 
opioids or past opioid use, there were no significant differences in the adjusted hazard ratio 
for death in all groups, compared to the current non-users (P > 0.05). Among survivors 1 
year after hip fracture, opioid past-use increased the risk of opioid sustained use by 1.52-fold 
(aRR; 95% CI, 1.45–1.8; P < 0.001).
Conclusion: Current use and past use of opioid did not increase all-cause mortality after hip 
fracture in elderly patients over 65 years of age. Past use of opioid before hip fracture increased 
risk of sustained use of opioid compared to the current opioid used without past use.
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INTRODUCTION
In the elderly population, hip fracture is a severe injury with high morbidity and mortality.1 
Substantial efforts are needed and medical costs are incurred in restoring function in elderly 
patients with hip fractures.1,2 Expecting an increase in hip fracture patients in the future, 
medical and institutional efforts are being made to reduce social costs. Among these, proper 
pain control is important to reduce delays in ambulation and complications, and to shorten 
the length of hospital stay.3
Elderly patients with hip fracture often use various medications for underlying comorbidities 
and are less likely to use more drugs due to decline in organ functions, such as the liver and 
kidneys.4 Nevertheless, intravenous or oral medications, such as opioids and non-steroidal 
anti-inflammatory drugs (NSAIDs), are commonly used to control postoperative pain.
Opioids can cause side effects, such as dizziness, sedation, balance problems, vomiting, 
constipation, and respiratory depression. Long-term use can lead to physical dependence 
and tolerance, and worst case, to addiction.5 However, the use of opioids has been increasing 
because they are a favorable option in terms of pain control.6 There have been several reports 
on opioid use in elderly patients with hip fractures. In a Danish nationwide cohort study, the 
proportion of opioid users increased after hip fracture surgery, and 16.8% of preoperative 
non-opioid users reported using opioids even after one year.7 A small cohort study by 
Lindestrand et al.4 reported that the use of opioids was not related to mortality. A'Court et 
al.2 evaluated the relationship between opioid use and operative methods and Maiese et al.8 
reported the cost to patients using opioids. Although these studies showed that the long-
term use of opioids was not beneficial for patients, they did not analyze the effects of opioid 
use in the acute phase of hip fracture in elderly patients, and some of the studies were not 
conducted using representative big data.
Thus, the purpose of this study was to assess the use of opioids before and after hip fracture 
in elderly patients in order to determine the effect of opioid use on all-cause mortality, and to 
analyze how opioid use before fracture increased the risk of sustained use after hip fracture, 
using a nationwide cohort.
METHODS
Study subjects
Incident hip fracture patients in our retrospective observational cohort study were identified 
from the Korean National Health Insurance Service-Senior cohort (NHIS-Senior).9 NHIS-
Senior consisted of 588,147 participants over 60 years of age (as of 2002) to represent 
elderly people in South Korea by simple 10% random sampling. All the individuals in the 
NHIS-Senior were followed until December 31, 2015, except those who were disqualified 
(emigration or death etc.). The NHIS has all personal information, such as medical 
utilization, demographics, and treatment information, for all Korean people.9-11
Elderly hip fracture cohort
The inclusion criteria for elderly hip fracture patients were as follows3: 1) first-time admission 
to an acute care hospital with diagnostic codes of femoral neck fractures (International 
Classification of Diseases, 10th Revision [ICD-10] S720) or intertrochanteric fractures (ICD-
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10 S721)12,13; 2) recipients of surgeries, including internal fixation (closed pinning [femur] 
and open reduction of a fractured extremity [femur]), hemiarthroplasty (hip), or total 
arthroplasty (hip); and 3) aged 65–99 years at the time of hip fracture to ensure the inclusion 
of osteoporotic hip fractures.13 To guarantee a one-year observation period, patients with 
hip fractures occurring less than 365 days before December 31, 2015 were excluded. Patients 
with their first hip fracture prior to December 31, 2004, were also excluded to ensure at least 
a 3-year hip fracture-free period. The last date of follow-up was defined as the date of death or 
December 31, 2015, whichever preceded. To identify opioid use during the acute phase, time 
zero (index date) was defined as 90 days after admission to an acute care hospital to fulfill the 
inclusion criteria for hip fractures in the elderly. Furthermore, to prevent immortal time bias, 
patients who died within 90 days after hip fracture were excluded from the study.
All-cause mortality
In the NHIS-Senior, each subject's unique de-identified number was linked to their vital 
statistics from the Korean National Statistical Office, including dates and causes of death.9 
The dates of death were used to calculate survival periods.
Categorization by type of opioid and definition of opioid exposure
The opioids used were hydromorphone, morphine, dihydrocodeine, oxycodone, 
hydrocodone, codeine, fentanyl, pentazocine, pethidine, buprenorphine, nalbuphine, 
butorphanol, tapentadol, remifentanil, sufentanil and tramadol.7,14,15 The opioids were 
classified into strong opioids (opioids other than tramadol) and tramadol.14 Patients who 
used both tramadol and strong opioids were classified as strong opioid users. Patients who 
had used opioids within six months before the hip fracture were defined as past users, and 
patients with no history of opioid use within six months before the hip fracture were defined 
as a past non-user. Patients who received opioids within three months after admission for hip 
fracture were defined as current users, and those who did not were defined as current non-
users. The cumulative dose of current tramadol and strong opioid was calculated by adding 
the amount of dispensed defined daily doses (DDDs).16 To determine the sustained use of 
strong opioids and tramadol, their use was investigated during the period from 3-months to 
1-year after hip fracture (sustained user).
The history of medication and use of antidiabetic, antihypertensive, anti-platelet agent, 
NSAIDs, steroids, COX-2 inhibitors, antidepressants, and benzodiazepines within 6-months 
before hip fracture and within 3-months after admission for hip fracture were investigated.
Statistical analysis
Demographics were identified at the time of admission. Survival time was defined in days 
as the period from the index date (at 90-days after admission) to the date of December 31, 
2015 or death, whichever preceded. Patients who died during the 90-day landmark period 
were excluded. A multivariable-adjusted Cox proportional hazard model was used to 
investigate the effects of tramadol and strong opioid use on all-cause mortality. The effect 
sizes are presented as hazard ratios (HRs) and 95% confidence intervals (CIs). A generalized 
estimating equation model with a Poisson distribution and logarithmic link function was 
used to estimate the adjusted rate ratios (aRRs) and 95% CIs to assess the association 
between past use and sustained use. The potential confounders included age group, gender, 
household income level, residential area, Charlson Comorbidity Score (CCS), type of 
fracture, surgery and anesthesia, calendar year of the hip fracture incidence, presence of 
transfusions, medication history, and recent medication use, which included strong opioids 
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and tramadol. Quan's ICD-10 coding algorithm of the CCS diagnostic codes during the 3 
years before admission for hip fracture was used to assess each subject's comorbidities.17 The 
presence of CCS disease-constituting categories was calculated by the presence of at least 2 
outpatient visits or 1 admission for primary or first secondary diagnosis. Statistical analyses 
were conducted using SAS Enterprise Guide version 7.1 (SAS Institute, Cary, NC, USA). 
Statistical significance was set at P < 0.05.
Ethics statement
The study design and protocol were approved by the Institutional Review Board of our 
hospital (EMC-IRB No 2018-01-010-001). Written informed consent was waived for all 
patients involved in our study.
RESULTS
Between January 1st, 2002, and December 31st, 2015, 19,915 patients with hip fractures were 
identified. Among these patients, 1,478 patients did not undergo surgery and 3,571 patients 
were excluded for not meeting the eligible criteria. In addition, 921 patients with a history 
of neoplasms and 1,018 patients who died within 90-days of hip fracture were excluded. 
Ultimately, 12,927 patients were included in our study (Fig. 1). The patient demographics 
and medication history and recent medication use are presented in Table 1. There were no 
significant differences in the cumulative mortality rates between the two groups (P < 0.05).
There were 7,384 (57.12%) opioid past users (5,951 [46.04%] tramadol past users, and 1,433 
[11.09%] strong opioids past users) (Fig. 1). The number of opioid current users increased 
to 11,467 (88.71%) after hip fracture, with the number of tramadol and strong opioid current 
users being 9,767 (75.56%) and 1,700 (13.15%), respectively. The number of patients with 
a sustained use of opioids decreased to 7,172 (55.48%) patients. The proportion of strong 
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1. non-operation (n = 1,478)
2. 3-year hip fracture-free period (n = 2,107)
3. under 1-year follow-up (n = 1,374)
4. age < 66 or > 99 (n = 90)
5. histories of neoplasm (n = 921)
6. died within 90 days after hip fractures (n = 1,018)
Fig. 1. Flowchart for the selection of the study subjects. 
NHIS-Senior = Korean National Health Insurance Service-Senior cohort.
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Table 1. Demographics and medication histories and crude mortality rate according to current use of opioid
Variables Current opioid non-user Current opioid user P value
Number 1,460 11,467
Age group 0.008
65–69 112 (7.7) 668 (5.8)
70–74 278 (19) 2,097 (18.3)
75–79 334 (22.9) 3,032 (26.4)
80–84 363 (24.9) 2,923 (25.5)
85–89 259 (17.7) 1,921 (16.8)
≥ 90 114 (7.8) 826 (7.2)
Sex 0.212
Male 354 (24.2) 2,613 (22.8)
Female 1,106 (75.8) 8,854 (77.2)
Income < 0.001
Low 585 (40.1) 5,106 (44.5)
Mid-low 344 (23.6) 2,654 (23.1)
Mid-high 267 (18.3) 2,087 (18.2)
High 264 (18.1) 1,620 (14.1)
Residential area 0.065
Metropolitan 559 (38.3) 4,679 (40.8)
Non-metropolitan 901 (61.7) 6,788 (59.2)
Charlson Comorbidity Score < 0.001
0 438 (30) 2,655 (23.2)
1–2 684 (46.8) 5,222 (45.5)
3–6 304 (20.8) 3,043 (26.5)
≥ 6 34 (2.3) 547 (4.8)
Fracture type 0.051
Neck fracture 811 (55.5) 6,059 (52.8)
Intertrochanter fracture 649 (44.5) 5,408 (47.2)
Surgery type 0.388
Hemiarthroplasty 721 (49.4) 5,747 (50.1)
Internal fixation 707 (48.4) 5,409 (47.2)
Total hip arthroplasty 32 (2.2) 311 (2.7)
Presence of transfusion (%) 1,084 (74.2) 8,464 (73.8) 0.722
Anesthesia < 0.001
General 244 (16.7) 2,802 (24.4)
Spinal 1,186 (81.2) 7,970 (69.5)
Unknown 30 (2.1) 695 (6.1)
Hospital beds < 0.001
< 200 136 (9.3) 2,695 (23.5)
200–499 191 (13.1) 2,120 (18.5)
500–799 653 (44.7) 3,902 (34)
≥ 800 480 (32.9) 2,750 (24)
Calendar year < 0.001
2006–2007 462 (31.6) 1,536 (13.4)
2008–2009 343 (23.5) 1,980 (17.3)
2010–2011 281 (19.2) 2,483 (21.7)
2012–2013 229 (15.7) 2,664 (23.2)
2014–2015 145 (9.9) 2,804 (24.5)
Past medication history < 0.001
Opioid non-user 859 (58.8) 4,684 (40.8)
Potent opioids past user 149 (10.2) 1,284 (11.2)
Tramadol past user 452 (31) 5,499 (48)
Antidepressant 428 (29.3) 4,189 (36.5) < 0.001
Benzodiazepine 922 (63.2) 8,059 (70.3) < 0.001
Anti-diabetic agent 315 (21.6) 3,163 (27.6) < 0.001
Anti-hypertensive agent 956 (65.5) 8,622 (75.2) < 0.001
NSAIDs 1,205 (82.5) 10,009 (87.3) < 0.001
COX-2 inhibitor 165 (11.3) 2,222 (19.4) < 0.001
Steroid 872 (59.7) 8,043 (70.1) < 0.001
Antiplatelet agent 614 (42.1) 5,822 (50.8) < 0.001
(continued to the next page)
opioid and tramadol current users increased in comparison to the proportion of past users 
in both categories, respectively. However, there was a greater increase in the number of 
tramadol current users than in strong opioid current users. The proportion of sustained 
users decreased to a level similar to that of past users, when compared to the proportion of 
current users (Fig. 2). The number of new users of tramadol and strong opioids among past 
non-users also increased after hip fracture. Moreover, the proportion of sustained users 
among new opioid users in the past non-user group decreased after one year. On death risk 
comparison according to current use and the DDD of strong opioids and tramadol in each 
patient group according to past opioid use, there were no significant differences in the 
adjusted HR compared to the current non-users in all groups (P > 0.05) (Table 2).
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Tramadol new user in past non-user
Strong opioid new user in past non-user
Past user Current user 3 mon–1 yr user 1–2 yr user
Hip fracture
Fig. 2. Trends in the percentage of opioid users before and after fracture in older patients with hip fractures.
Variables Current opioid non-user Current opioid user P value
Recent medication history
Antidepressant 230 (15.8) 2,269 (19.8) < 0.001
Benzodiazepine 512 (35.1) 4,728 (41.2) < 0.001
Anti-diabetic agent 307 (21) 3,077 (26.8) < 0.001
Anti-hypertensive agent 857 (58.7) 7,997 (69.7) < 0.001
NSAIDs 1,344 (92.1) 9,873 (86.1) < 0.001
COX-2 inhibitors 202 (13.8) 2,792 (24.3) < 0.001
Steroids 420 (28.8) 3,886 (33.9) < 0.001
Antiplatelet agents 416 (28.5) 4,103 (35.8) < 0.001
Cumulative mortality rate
30-days 22 (1.5) 196 (1.7) 0.572
60-days 50 (3.4) 348 (3) 0.417
90-days 65 (4.5) 463 (4) 0.451
180-days 117 (8) 779 (6.8) 0.084
1-year 184 (12.6) 1,376 (12) 0.505
Values are presented as number (%).
NSAIDs = non-steroidal anti-inflammatory drugs.
Table 1. (Continued) Demographics and medication histories and crude mortality rate according to current use of 
opioid
Among those who survived up to one year after hip fracture (1,376 patients died before 1-year 
after hip fracture), opioid past-use increased the risk of opioid sustained use by 1.52-fold 
(aRR; 95% CI, 1.45–1.8; P < 0.001). Tramadol and strong opioid past-use in current users 
increased the risk of a sustained use of tramadol and strong opioid by 1.49-fold (aRR; 95% CI, 
1.43–1.56; P < 0.001) and 1.57-fold (aRR; 95% CI, 1.4–1.76; P < 0.001), respectively, compared 
to past non-users (Table 3).
DISCUSSION
The main findings of this study are as follows. First, the current and past use of opioids did 
not increase all-cause mortality after hip fractures in elderly patients. Second, the opioid 
prescription rate increased rapidly within three months after hip fracture compared to before 
the hip fracture, but decreased three months after hip fracture. Third, current users with a 
history of opioid use had a higher risk of sustained opioid use compared to those who did not.
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Table 2. Comparison of hazard for death according to current use and DDD of opioid in each patient group 
according to the presence of past opioid use
Variables aHR (95% CI) P value
Included all patients (n = 12,927)
Current non-user (n = 1,460) 1 (reference)
Opioid current user (n = 11,467) 0.94 (0.87–1.01) 0.091
Potent opioid DDD ≤ 30 (n = 1,328) 1.00 (0.94–1.06) 0.987
30 < Potent opioid DDD (n = 372) 0.95 (0.87–1.03) 0.235
Tramadol DDD ≤ 30 (n = 9,372) 0.95 (0.90–1.01) 0.124
30 < Tramadol DDD (n = 395) 0.91 (0.77–1.08) 0.295
Past opioid non-user (n = 5,543)
Current non-user (n = 859) 1 (reference)
Opioid current user (n = 4,684) 0.93 (0.84–1.03) 0.159
Potent opioid DDD ≤ 30 (n = 661) 1.01 (0.93–1.10) 0.795
30 < Potent opioid DDD (n = 150) 0.96 (0.84–1.10) 0.533
Tramadol DDD ≤ 30 (n = 3,764) 0.95 (0.87–1.03) 0.213
30 < Tramadol DDD (n = 109) 0.85 (0.63–1.15) 0.299
Past opioid user (n = 7,384)
Current non-user (n = 601) 1 (reference)
Opioid current user (n = 6,783) 0.94 (0.84–1.07) 0.356
Potent opioid DDD ≤ 30 (n = 667) 0.99 (0.91–1.07) 0.741
30 < Potent opioid DDD (n = 222) 0.95 (0.85–1.05) 0.308
Tramadol DDD ≤ 30 (n = 5,608) 0.97 (0.89–1.06) 0.448
30 < Tramadol DDD (n = 286) 0.96 (0.78–1.18) 0.682
DDD = defined daily dose, aHR = adjusted hazard ratio, CI = confidence interval.
Table 3. In the opioid current user, the relationship between past user and sustained user of opioid in survivors 
until 1 year after hip fracture
Type of opioid user Sustained (3 mon–1 yr) user aRR (95% CI) P value
Opioid current user (n = 10,091)
Past non-user (n = 4,048) 1,652 (40.8) 1 (reference)
Past user (n = 6,043) 4,290 (71) 1.52 (1.45–1.58) < 0.001
Tramadol current user (n = 8,606)
Past non-user (n = 3,350) 1,400 (41.8) 1 (reference)
Past user (n = 5,256) 3,779 (71.9) 1.49 (1.43–1.56) < 0.001
Potent opioid current user (n = 1,485)
Past non-user (n = 698) 252 (36.1) 1 (reference)
Past user (n = 787) 511 (64.9) 1.57 (1.4–1.76) < 0.001
Values are presented as number (%).
aRR = adjusted rate ratio, CI = confidence interval.
In 1995, the American Pain Society reported pain as a fifth vital sign that should be treated 
appropriately.18 This change in the concept of drug prescriptions for pain control increased 
the prescription of opioids, resulting in increased patient satisfaction. Since then, opioids 
have become an essential component of multimodal postoperative analgesia and are still 
widely used.19 However, this trend has led to opioid abuse for chronic musculoskeletal pain 
in the United States and Europe, and has emerged as a social problem.20,21 Birke et al.20 
reported that the use of opioids for non-cancer pain in a Danish population was highest in 
those aged 65 years and older. Several studies have shown that the side effects of opioids, 
such as cognitive impairment, dizziness, addiction, mortality, increased fall and fracture risk, 
are more likely to occur in elderly patients.22,23 Paradoxically, insufficient pain control can 
lead to delirium, day-night inversion, and depression.2
Opioid-related deaths are among the most frequent types of drug-related deaths.24 Summers 
et al.25 reported that hip fracture patients with opioid use disorders had higher mortality 
rates than hip fracture patients with non-opioid use disorders. Patients with opioid use 
disorder had more comorbidities than those who did not. Therefore, they should be 
distinguished from patients with a history of opioid use. Lindestrand et al.4 investigated 
the use of opioids in patients with hip fractures and the potential relationship between 
the perioperative prescription of opioids, mortality, and chronic opioid use. In their study, 
the 30-day mortality rate was 10% and 1-year mortality rate was 27%. They found that 
mortality was associated with old age and increased comorbidities, but was not associated 
with opioid use. Therefore, they suggested that there was no general reason to refrain 
from prescribing opioids to hip fracture patients based on a fear of increased mortality. 
Our results are consistent with these findings. Tramadol has a lower analgesic potency 
than strong opioids, but is relatively safer due to a lower risk of respiratory depression and 
addiction.26 Therefore, we expected that all-cause mortality would be higher in the group 
using potent opioids at follow-up in both groups. However, neither tramadol nor strong 
opioids increased all-cause mortality. In addition, we found that opioid use before and after 
hip fracture did not contribute to increased mortality. Our study also showed that there was 
no increase in mortality even in groups taking high opioid doses after hip fracture, when 
compared to the non-user group. In elderly patients, the combination of several drugs is an 
important issue, and there are reports that the combination of central nervous system active 
drugs, including benzodiazepines and tricyclic antidepressants, with opioids can increase 
mortality.27,28 However, our study found that opioids, after adjusting for several other 
drugs, including benzodiazepines and tricyclic antidepressants, did not significantly affect 
postoperative mortality.
Most recently, a large epidemiological study on opioid use after hip fracture surgery was 
published in Denmark. The authors performed a cohort study that included all patients (65 
years old and over) who underwent hip fracture surgery (from 2005 to 2015), as selected 
from the Danish Multidisciplinary Hip Fracture Database.7 In their study, similar to the 
results of our study, the rate of opioid users increased rapidly after hip fracture and then 
decreased. They also found that the proportion of opioid users increased after hip fracture 
surgery and increased by 1.4% in the fourth quarter compared to before hip fracture. Of the 
opioid nonusers before surgery, 16.8% were opioid users in the fourth quarter after surgery. 
They suggested that opioid use at 1-year after surgery for hip fracture was common, both in 
patients who were opioid users and non-users before surgery. However, opioids are essential 
for postoperative pain control. In addition, depending on the degree of fracture reduction 
or the result of surgery, chronic pain or complications may persist, and pain control may be 
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necessary. Therefore, it is necessary to detect and be aware of the risk of future abuse among 
patients who currently need opioids.
Simoni et al.7 reported that 8.3% of opioid non-users and 52.3% of opioid users before surgery 
used opioids one year after surgery. Morris and Mir29 also reported that pre-injury opioid users 
among orthopedic trauma patients had a high risk of postoperative opioid abuse. In addition, 
the use of preoperative opioids among orthopedic patients has been reported to cause poor 
clinical outcomes and increase the risk of reoperation.30,31 We also found that among the 
current opioid users within three months after fracture, patients with a history of opioid use 
within six months prior to the fracture had a higher risk of sustained opioid use. This finding 
is in agreement with the results of a study that reported that preoperative opioid experience 
could increase the likelihood of opioid abuse.32 This may be due to dependence of past opioid 
use or opioid-induced hyperalgesia, making it difficult to discontinue opioids.33 Thus, before 
opioids are used after hip fracture surgery, a history of opioid use before the fracture should 
be carefully noted. Furthermore, for past opioid users, care should be taken not to prescribe 
opioids for a long period of time. In addition, it is necessary to follow-up to assess dependence 
or addiction in patients using opioids after surgery.
This study has several limitations. First, there was no analysis of functional or pain scores 
for hip fracture treatment. Therefore, there was no analysis of the effect of opioids on 
functional aspects or pain control. Second, since this study was solely based on a South 
Korean database, it may have had potential biases, such as regional and cultural biases. 
Spain and Sweden are both European countries, but the rate of opioid use before hip fracture 
was different between the two countries. As such, the guidelines for opioid use and medical 
systems are different in each country.4 However, this study compared the relative risk of 
mortality and the sustained use of opioids between subgroups. Third, our study did not 
define addiction. Drug addiction is not simply defined by dosage, but various factors such as 
dependence must be considered. Fourth, the specific cause of death could not be analyzed 
because of inherent limitations in the claims database.
In conclusion, the current use and past use of opioids did not increase all-cause mortality after 
hip fracture in elderly patients over 65 years of age. In current opioid users, past use of opioids 
before hip fracture increased the risk of sustained use of opioids compared to those without.
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